source
- Sandoz to Pay $478.5 Million to Settle Generic Drug Price-Fixing ClaimsSandoz has agreed to pay $478.5 million to resolve allegations that it participated in a widespread conspiracy to inflate and manipulate the prices of generic medicines. Dozens of U.S. states and i…
- Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cutsAngus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…